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Association between allergic 
conditions and risk of prostate 
cancer: A Prisma-Compliant 
Systematic Review and Meta-
Analysis
Jianguo Zhu1,2,3,*, Jukun Song4,*, Zezhen Liu1,2,*, Jin Han5, Heng Luo1,2, Yunlin Liu6, 
Zhenyu Jia1,2, Yuanbo Dong3, Wei Zhang4, Funeng Jiang1,2, Chinlee Wu1,7, Zaolin Sun3 & 
Weide Zhong1,2
Association between allergic conditions and prostate cancer risk has been investigated for many 
years. However, the results from available evidence for the association are inconsistent. We conducted 
a meta-analysis to evaluate the relationship between allergic conditions (asthma, atopy, hay fever 
and “any allergy”) and risk of prostate cancer. The PubMed and Embase databases were searched to 
screen observational studies meeting our meta-analysis criteria. Study selection and data extraction 
from included studies were independently performed by two authors. Twenty studies were considered 
eligible involving 5 case-control studies and 15 cohort studies. The summary relative risk (RR) for 
developing prostate cancer risk was 1.04 (95%CI: 0.92–1.17) for asthma, and 1.25 (95%CI: 0.74–2.10) for 
atopy, 1.04 (95%CI: 0.99–1.09) for hay fever, 0.96 (95%CI: 0.86–1.06) for any allergy. In the Subgroup 
and sensitivity analysis, similar results were produced. Little evidence of publication bias was observed. 
The present meta-analysis of observational studies indicates that no indication of an association 
between allergic conditions and risk of prostate cancer was found, and the meta-analysis does not 
support neither the original hypothesis of an overall cancer protective effect of allergic conditions, nor 
that of an opposite effect in the development of prostate cancer.
Prostate cancer is one of most frequently diagnosed cancer in Western countries and is the second most common 
cancer in men, following lung cancer, worldwide1,2. In 2015, up to 220,800 men were diagnosed with prostate can-
cer, and 27,540 men will die of it in the United States1. The incidence and mortality rates of prostate cancer vary 
markedly among different ethnic groups, with the lowest rates found in China and other parts of Asia and the high-
est rates detected in Western populations3. The etiology of prostate cancer comprises multiple factors. Established 
risk factors for prostate cancer included obesity, old age, ethnicity, androgen, and environmental factor, 
androgen, and diet4–7. There are some studies addressing systematic inflammation conditions and immune 
response that contribute to prostate tumorigenesis8,9.
Allergy-related carcinogenesis is a topic of interest but has generated considerable controversy. Considering 
the impact of the prostate cancer risk potentially resulting from allergic diaseases, a number of studies have 
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explored the association between allergic diseases and prostate cancer risk10–19. However, individual studies have 
yielded inconsistent or conflicting findings, possibly caused by limitation associated with an individual study. In a 
previous meta-analysis of studies (only included nine studies), asthma, hay fever and allergy were not associated 
with prostate cancer risk, but not for atopy20. Two additional studies were not included in the meta-analysis21,22. 
Subsequent publishing studies have also found inconsistent results of associations between allergic disease and 
prostate cancer risk, with positive association23–26, inverse association27, and no association28–31. To shed light 
on these contradictory results and to more precisely evaluate the relationship among allergic diseases and pros-
tate cancer, we performed an up-dated meta-analysis of published studies. Nevertheless, clarifying a relationship 
might emphasize the importance of considering additional preventative methods for prostate cancer. The study 
was reported in accordance with the Preferred Reporting Items for Systematic Reviews32.
Results
Literature search. Following the development of our search strategy, 1,890 records were initially retrieved. 
After excluding the duplicates and articles that did not meet the inclusion criteria, we reviewed 34 possible rele-
vant studies in full-text. A total of 14 studies were excluded for the following reasons: Two articles were covered 
the same population27,31; six articles were narrative reviews33–38; one article reported the association allergic dis-
orders and pancreatic cancer39; and six articles were not related to outcome of interest40–45. Finally, 20 studies that 
met inclusive criteria were included in the meta-analysis (Fig. 1).
Study characteristics. The Tables 1 and 2 shows the descriptive data for all included studies. A total of 20 
studies, comprising 5 case-control studies with 2,924 incident cases and 7,175 controls and 15 cohort studies 
including 16,526 cases and 1,681,562 pariticipants, contributed to the meta-analysis. These studies were published 
from 1985 to 2015. The number of prostate cancer patients ranged from 1 to 6,294 in the case-control studies and 
from 10 to 1,936 in the cohort studies. Ten studies were conducted in Europe10,12–14,17,23,24,28–30, six in the North 
America11,16,18,19,22,31, two in Australia15,25 and two in Asia21,26. Eighteen studies reported findings for prostate can-
cer incidence10–14,16–19,21–26,28,29,31, whereas only two studies reported results for prostate cancer mortality16,30. We 
included a total of 5,757 prostate cancer deaths, 16,526 prostate cancer cases in the meta-analysis. The maximum 
numbers (1,102,247) of participants were from the Canada prospective study and minimum number (1,522) 
were from Australia prospective study in the cohort studies, while the maximum incident patients (1,936) were 
from the Canada Montreal PROtEuS study and minimum incident patients (10) were from Japan study in the 
case-control studies. The exposure categories that were measured were: 1) asthma; 2) hay fever (rhinitis); 3) 
atopy; and 4) any allergy (atopy and/or asthma, hay fever, or other allergic disease). For the assessment of allergic 
conditions, allergen-specific IgE measurement, skin prick testing, self-reported questionnaire, interviews by med-
ical staff, and hospital discharge register were employed. For the assessment of prostate cancer, fourteen studies 
reported that cancers were histologically confirmed or were identified from national/regional cancer registeries, 
which we assumed verified the cancer pathologically. The remaining studies based their cancer diagnoses on dif-
ferent criteria; admission/discharge diagnoses; an automated general practice database; a linked national death 
register; review of hospital and nursing home recorder and death certificates. Six studies were designed to evaluate 
OR10,17–19,22,31, five evaluated HR15,25,26,29,30, three evaluated RR11,16,21,28, while five studies compared observed can-
cer incidence rates in cohort of patients with asthma or hay fever/allergic rhinitis against expected numbers 
estimated from population-based cancer registries and their effect estimates were standardized incidence ratio 
(SIR)13,14,23,24 or standardized mortality ratio(SMR)12.
Adjusted effect estimates could be determined for most cohort and case-control studies. Most risk esti-
mates were adjusted for age (n = 12)10,11,15,17–19,22,25,26,28,30,31, smoking (n = 10)10,11,15–19,25,28,29 and body mass 
Figure 1. Flow diagram of selection of studies included in the meta-analysis. 
www.nature.com/scientificreports/
3Scientific RepoRts | 6:35682 | DOI: 10.1038/srep35682
Study Year Country Study design No. of cases
Cohort 
size
Study 
period
Age, Median 
(Range), yrs Exposure
Exposure 
assessment
Cancer 
identification
Follow-up 
period 
(years)
Adjustment for 
covariates
Mcwhorter 1988 USA
A prospective 
cohort study 
(NHANESI)
34 6108 1971–1984 NA(25–74) Any allergy
The physician-
diagnosed 
allergy
Hospital 
or nursing 
home records 
or on death 
certificate
10
Adjusted for age, 
race, and smoking 
status.
Mills 1992 USA A cohort study 180 34,198 1977–1982 NA
Asthma; 
hay fever; 
any allergy
A detailed 
life-style 
questionnaire on 
medical history
Medical 
records 
and cancer 
registries
6
Adjusted age, 
smoking history, 
and time since last 
physician contact.
Kallen 1993 Sweden A cohort study 671 64,346 1969–1983 NA Asthma
Hospital 
discharge 
register
Swedish cancer 
registries and 
death registries
14 NA
Vesterinen 1993 Finland A cohort study 256 77,952 1970–1987 NA(35–84) Asthma
Finish social 
insurance 
institution’s 
file of asthma 
patients
Finnish cancer 
registry 17 NA
Eriksson 1995 Sweden A cohort study 1 6,593 1976–1989 31(16–80) Asthma Skin prick tests;
Swedish 
national tumor 
registries
13 NA
Talbot-
Smith 2002 Australia
A prospective 
cohort study 86 1,522 1981–1999
Men:50.7; 
Women:50.0
Asthma; 
hay fever; 
atopy
Self-reported 
physician-
diagnosed 
allergy and skin 
prick testing
Linkage 
to death 
registrations 
and Australian 
cancer registry
8
Adjusted for age, 
smoking status, and 
body mass index.
Gonzalez-
Perez 2005 Spain
A nested 
case-control 
study
407 9,488 1994–2000 NA(20–79) Asthma
Automated 
general 
practitioner 
records
Automated 
general 
practitioner 
records
6
Adjusted for age, 
calendar year, BMI, 
alcohol intake, 
smoking status, 
prior comorbidities 
(cardiovascular 
disease, diabetes, 
osteoarthirtis, 
and rheumatoid 
arthritis), health 
services utilization, 
use of aspirin, 
NSAID, and 
paracetamol using 
logistic regression.
Turner 2005 Canada A prospective cohort study
5,674 
(mortality) 1,102,247 1982–2000 NA(≥ 30)
Asthma; 
hay fever; 
any allergy
Self-reported 
physician-
diagnosed 
allergy
National death 
index 18
Adjusted for race, 
smoking, education, 
body mass index, 
exercise, alcohol 
drinking, family 
history of prostate 
cancer, and 
consumption of 
vegetables, fat, and 
red meat.
Ji 2009 Sweden A cohort study 1008 140,425 1965–2004 NA Asthma
The Swedish 
hospital 
discharge 
register
Cancer 
register-
identified cases
40 NA
Severi 2010 Australia
A prospective 
cohort study 
(Melbourne 
Collaborative 
Cohort Study 
(MCCS))
1,179 16,394 1990–2007 NA(27–81) Asthma
A structure 
interview 
schedule 
and history 
of medical 
conditions
Australia state 
cancer registry 13.4
Adjusted for age, 
country of birth, 
education, body 
mass index, fat 
and fat-free mass, 
smoking, alcohol 
consumption, and 
total energy intake.
Hemminki 2014 Swede A cohort study 404 138,723 1964–2010 NA
Hay fever/
allergic 
rhinitis
Hospital 
Discharge 
Register
Swedish 
Cancer 
Registry
NA NA
Skaaby 2014 Danish
A prospective 
population-
based cohort 
study
175 14,849 1976–2008
Nonatopic: 
46.3 ± 10.9; 
Atopic 
43.7 ± 10.4
Atopy
Serum specific 
IgE positivity 
measurements
Danish cancer 
registry 11.8
Adjusted for age (age 
is underlying time 
axis), education, 
physical activity, 
smoking habits, 
alcohol intake, and 
BMI.
Continued
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index (n = 8)10,15–17,25,28–30. Some studies were also controlled for alcohol consumption (n = 5)10,16,17,25,29 and 
race (n = 3)16,19,28, but few studies were adjusted for family history of prostate cancer (n = 2), total energy intake 
(n = 1)25, and intake of vegetable and red meat (n = 1)16. None of the studies were adjusted for exposure to heavy 
metals and androgen.
The methodological quality of the included studies was generally good. The NOS scores ranged from five to 
seven (Table 3). The median NOS score was 6.0.
Asthma and risk of prostate cancer. The association of asthma with prostate cancer was investigated 
in 17 studies10–18,21,22,24–26,28,30,31. Thirteen studies reported HR/RR/OR10,11,15–18,21,22,25,26,28,30,31, while four studies 
reported the SIR/SMR12–14,24. The combined relative risk was 1.04 (95%CI: 0.92–1.17), with significant hetero-
geneity (Pfor heterogeneity = 0.000; I2 = 73.2%), while the pooled SIR was 1.00 (95%CI: 0.68–1.47), with significant 
heterogeneity (Pfor heterogeneity = 0.000; I2 = 97.7%) (Fig. 2). In subgroup and sensitivity analysis, the results showed 
basically consistent with the overall analysis (Table 4). When we stratified the analysis by geographic region, the 
pooled RR was 0.95 (95%CI: 0.81–1.12) for studies conducted in North America, 0.90 (0.81–1.00) for studies con-
ducted in Europe, and 4.55 (0.23–89.94) for studies conducted in Asia. In the subgroup analysis stratified by NOS 
quality, the combined RR was 1.90 (95%CI: 0.29–12.61) for low quality studies and 1.02 (95%CI: 0.93–1.13) for 
high quality studies. We restricted each analysis to study design, the combined RR was 1.02 (95%CI: 0.91–1.15) 
among case-control studies and 1.20 (94%CI: 0.69–2.09) among cohort studies, respectively. Nevertheless, when 
we stratified the analysis by adjusted for age, race, BMI, cigarette smoking and alcohol drinking, asthma was 
also not associated with risk of prostate cancer. In a sensitivity analysis, similar results were observed, which 
ranged from 1.01 (95%CI: 0.88–1.16) with significant heterogeneity (Pfor heterogeneity = 0.000, I2 = 73.7%) (excluding 
the study by Severi G et al.25) to 1.07 (95%CI: 0.93–1.23) with significant heterogeneity (Pfor heterogeneity = 0.000, 
I2 = 69.2%) (excluding the study by Platz et al.28). Only four of studies on asthma specially investigated advanced 
prostate cancer risk (advanced prostate cancer was defined as T3-4 and PSA > 50 ng/ml or Gleason grade ≥ 8) and 
asthma25,28, the summary RR was 0.86 (95%CI: 0.54–1.37), with significant heterogeneity (Pfor heterogeneity = 0.079; 
I2 = 67.6%). Egger funnel plot asymmetry test (P = 0.865) and Begg rank correlation test (P = 0.502) were 
performed to assess publication bias and the funnel plot symmetry (Fig. 3) was examined. Finally, no proof of 
publication bias was obtained. Because of limited number of studies, we fail to conduct subgroup and sensitivity, 
publication analysis for studies reported the SIR or SMR.
Hay fever and risk of prostate cancer. The association of hay fever with prostate cancer was examined 
in 7 studies10,11,16,18,23,28,31. The six studies reported RR/OR10,11,16,18,28,31 (Fig. 4), while SIR was reported in only one 
Study Year Country Study design No. of cases
Cohort 
size
Study 
period
Age, Median 
(Range), yrs Exposure
Exposure 
assessment
Cancer 
identification
Follow-up 
period 
(years)
Adjustment for 
covariates
Platz 2015 Sweden
A prospective 
population-
based cohort 
study (Health 
Professionals 
Follow-up 
Study)
6294 47, 880 1986–2012 NA(40–75) Asthma; hayfever Queationnaire
Medical and 
pathology 
reports (90%)
26
Adjusted for age, race 
(African-American, 
Asian, other ancestry 
and white), first-
degree family history 
of prostate cancer, 
height (inches), body 
mass index (BMI, 
kg/m2, updated), 
BMI at the age of 
21 years (kg/m2), 
vigorous physical 
activity (MET-hours/
week, updated), 
diabetes (updated) 
and cigarette 
smoking in the past 
10 years (pack-years, 
updated).
Su 2015 Taiwan (China)
A 
population-
based case-
cohort study
74 12,372 1997–2008 54.87 (15–65+) Asthma
Medical claims 
data
Prostate 
cancer claim 
records and 
histopathologic 
findings or 
significantly 
elevated 
prostate-
specific antigen 
with radiologic 
evidence of 
metastasis
5.05
Adjusted for age, 
residential area, 
insurance premium, 
hypertriglyceridemia, 
hypertension, 
diabetes mellitus, 
chronic obstructive 
pulmonary disease, 
duration of 
hospitalization, and 
mortality.
Taqhizadeh 2015 Netherlands
A general 
population-
based cohort 
study
83(mortality 
and 
hospitalization)
8,465 1965–2008 NA(20–65) Asthma
Peripheral blood 
eosinophil 
counts; Skin 
prick tests; 
Serum total 
Immunoglobulin 
E (IgE)
Hospital 
admission 
register
43
Adjusted for age, 
Forced Expiratory 
Volume in 1 s (FEV 
1) as % of predicted, 
BMI (all at the first 
survey), and place of 
residence.
Table 1. Characteristic of cohort/nested case-control studies included in the meta-analysis.
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study, which reported a positive association between hay fever/allergic rhinitis and prostate cancer risk23. The 
combined relative risk was 1.04 (95%CI: 0.99–1.09), with low heterogeneity (Pfor heterogeneity = 0.428; I2 = 0.0%). 
Subgroup and sensitivity analysis produced similar results (Table 4). In subgroup analysis stratified by geographic 
region, asthma was not associated with risk of prostate cancer (RR: 0.97; 95% CI: 0.88–1.06) in the four studies in 
North Ameria, but not in the two studies in Europe (RR:1.07; 95%CI: 1.01–1.13). Compared with a low NOS score 
(RR = 1.02, 95%CI: 0.94–1.11), the association was higher among studies with high NOS score (RR = 1.15, 95% 
CI: 0.78–1.70). When we restricted each analysis to study design, the combined RR was 1.03 (95%CI: 0.93–1.14) 
among case-control studies and 1.02 (95%CI: 0.76–1.36) cohort studies, respectively. When the analysis was 
restricted to studies adjusted for race, BMI and cigarette smoking, we found no association between asthma 
and prostate cancer, but not for studies adjusted for age and alcohol drinking. In a sensitivity analysis, similar 
results were observed, which ranged from 0.97 (95%CI: 0.88–1.06) with low heterogeneity (Pfor heterogeneit = 0.360, 
I2 = 9.0%) (excluding the study by Platz et al.28) to 1.07 (95%CI: 1.01–1.13) with significant heterogeneity 
(Pfor heterogeneit = 0.025, I2 = 58.4%) (excluding the study by Turne et al. which reported the association between 
Study Year Country Study design
No. of 
cases
No. of 
controls
Study 
period
Age, Median 
(Range), yrs Exposures
Exposure 
assessment
Cancer 
identification
Adjustment for 
covariates
Vena 1985 USA
A retrospective 
case-control 
study
263 1562 1957–1965 NA Asthma, hay fever
Self-completed 
questionnaire and 
medical history 
interview
Admissions 
with cancer
Adjusted for age 
and smoking.
Ohrui 2002 Japan A case-control study 10 1202 1995–2000
Case:68; 
control:69 Asthma Clinical diagnosis
Clinical 
diagnosis NA
Wang 2006 Germany A case-control study 318 1904 2000–2003 NA(50–74)
Asthma, hay 
fever, atopy, any 
allergy
Allergen-specific 
LgE measurement; 
questionnaire 
on physician 
diagnosed allergy
Histologically 
confirmed 
cancers
Adjusted for 
age, education, 
body mass index, 
family history 
of cancer (first 
degree), smoking 
status and alcohol 
consumption.
El-Zein 2010 Canada (Montreal)
A population-
based case-
control study
397 512 1979–1986 NA(35–70) Ashtma, eczema
Self-reported 
history of medical 
conditions
Histologically 
confirmed 
cancers.
Adjusted for 
age, income, 
respondent status, 
ancestry, smoking, 
and farming.
Weiss 2014 Canada (Montreal)
A population-
based case-
control study 
(Montreal 
PROtEuS study)
1936 1995 2005–2009 Case:63.6; Control 64.8
Asthma, 
allergy; hay 
fever
Self-reported 
asthma and allergy
Que´becn 
Tumour 
registery 
(80%)
Adjusted for age, 
ancestry and 
familial history of 
prostate cancer.
Table 2.  Characteristic of case-control studies included in the meta-analysis.
Author year Selection Comparability Exposure
Vena 1985 2 1 2
Mcwhorter 1988 3 1 2
Mills 1992 3 1 1
Kallen 1993 3 0 2
Vesterinen 1993 3 0 2
Eriksson 1995 3 0 2
Ohrui 2002 3 0 2
Talbot-Smith 2002 3 1 2
Lightfoot 2004 3 1 2
Turner 2005 3 2 2
Gonzalez-Perez 2005 3 2 2
Wang 2006 3 2 2
Ji 2009 3 0 2
Severi 2010 3 2 2
Hemminki 2014 3 0 2
Weiss 2014 3 1 2
Skaaby 2014 3 2 2
Platz 2015 3 2 2
Su 2015 3 2 2
Taqhizadeh 2015 3 2 2
Table 3.  Quality assessment of eligible studies based on Newcastle-Ottawa scale.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:35682 | DOI: 10.1038/srep35682
asthma and mortality of prostate cancer16). Both the Begg rank correlation test (P = 0.707) and the Egger lin-
ear regression test (P = 0.775) in the meta-analysis indicated no significant publication bias. Because number of 
included studies less than 10, we did not perform the funnel plot.
Atopy and risk of prostate cancer. The association of atopy with prostate cancer was investigated in 3 
studies10,15,29. The combined relative risk was 1.25 (95%CI: 0.74–2.10), with notable heterogeneity (Pfor heterogeneity 
= 0.024; I2 = 73.2%) (Fig. 5). In subgroup and sensitivity analysis, the results showed basically consistent with 
the overall analysis (Table 4). The include studies achieved six or more stars and considered to be of high qual-
ity, so the result was consistent with overall analysis. When the analysis was restricted to studies adjusted for 
age, race, BMI, alcohol drinking and cigarette smoking, we found no association between asthma and pros-
tate cancer. In a sensitivity analysis, similar results were observed, which ranged from 1.05 (95%CI: 0.62–1.77) 
with low heterogeneity (Pfor heterogeneity = 0.036, I2 = 77.6%) (excluding the study by Talbot-Smith et al.15) to 1.59 
(95%CI: 0.93–2.71) with significant heterogeneity (Pfor heterogeneity  = 0.193, I2 = 41.0%) (excluding the study by 
Skaaby et al.29). Both Egger’s test (P = 1.000) and Bgger’s test (P = 0.761) showed no publication bias. Because 
number of included studies less than 10, we did not perform the funnel plot.
Any allergy and risk of prostate cancer. The association of asthma with prostate cancer was inves-
tigated in 6 studies10,11,16,19,22,31. The combined relative risk was 0.96 (0.86–1.06), with low heterogeneity 
(Pfor heterogeneity = 0.287; I2 = 19.3%). Subgroup and sensitivity analysis yielded similar result (Fig. 6). In subgroup 
and sensitivity analysis, the results showed basically consistent with the overall analysis (Table 4). When we strat-
ified the analysis by geographic region, the pooled RR was 0.96 (95%CI: 0.84–1.10) for 5 studies conducted in 
North America, 0.98 (95%CI: 0.66–1.45) for 1 studies conducted in Europe. Stratifying by study design, the com-
bined RR was 1.06 (95%CI: 0.84–1.33) among case-control studies and 0.88 (95%CI: 0.75–1.04) among cohort 
studies, respectively. Compared with a low NOS score (SMR = 2.08, 95%CI: 0.73–5.91), the association was sig-
nificant among studies with high NOS score (OR = 1.51, 95%CI: 1.14–1.98). In subgroup analysis adjusted for 
risk factors, including age, race, smoking and alcohol drinking, the results was consistent with overall analysis. 
In a sensitivity analysis, similar results were observed, which ranged from 0.93 (95%CI: 0.86–1.00) with low het-
erogeneity (Pfor heterogeneity = 0.612, I2 = 0.0%) (excluding the study by Mill et al.11) to 0.99 (95%CI: 0.82–1.19) with 
significant heterogeneity (Pfor heterogeneity = 0.194, I2 = 34.1%) (excluding the study by Turner et al.16). The Begg rank 
correlation test (P = 0.133) and Egger linear regression test (P = 0.489) also indicated no evidence of publication 
bias. Because number of included studies less than 10, we did not perform the funnel plot.
Discussion
Allergic diseases (immune mediated conditions), encompassing hay fever, allergic asthma and atopy, are 
caused by inappropriate immunological response to antigens that do not elicit response in most individuals. 
Allergy-related carcinogenesis is a topic of interest but has generated considerable controversy. There has been 
a long-standing interest in determining whether individuals with allergic diseases have an altered risk of devel-
oping cancer. Several studies investigated the association between allergic diseases and specific cancers. Asthma, 
hay fever, and atopy have been associated with the risk of several specific cancers, such as pancreatic cancer, 
lymphomas, brain tumors, breast cancer and leukemia, although inconsistently10,14,15,46,47. Allergic diseases could 
Figure 2. Forest plot of asthma and relative risk/standardized incidence ratio of prostate cancer. 
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theoretically both prevent and induce the development of several specific cancers. Two hypotheses that attempt 
to explain the possible mechanism between allergic diseases and cancer are immune surveillance and the anti-
genic stimulation theory48. Allergy might enhance the human immune system to recognize and eliminate can-
cer cells. In contrast, the antigenic stimulation hypothesis proposes that hyperactive immune conditions trigger 
chronic cellular inflammation, resulting in DNA mutation in dividing cells and inevitably leading to cancer devel-
opment49. The determination of whether asthma, hay fever, atopy and any allergy are associated with prostate 
Subgroup 
analysis
Asthma Hay fever Atopy Any allergy
N RR(95%CI) I2(%) P value N RR(95%CI) I2(%) P value N RR(95%CI) I2(%) P value N RR(95%CI) I2(%) P value
Total 13 1.04(0.92–1.17) 73.2 0.000 6 1.04(0.99–1.09) 0.0 0.428 3 1.25(0.74–2.10) 73.2 0.024 6 0.96(0.86–1.06) 19.3 0.287
Study design
 Cohort study 8 1.02(0.91–1.15) 68.0 0.003 3 1.03(0.93–1.14) 56.1 0.103 2 1.31(0.43–4.01) 81.9 0.019 3 1.06(0.84–1.33) 48.9 0.142
  Case-control 
study 5 1.20(0.69–2.09) 82.5 0.000 3 1.02(0.76–1.36) 0.0 0.848 1 1.35(1.00–1.83) NA NA 3 0.88(0.75–1.04) 0.0 0.497
Geographic region
  North 
America 5 0.95(0.81–1.12) 20.9 0.281 4 0.97(0.88–1.06) 0.0 0.699 5 0.96(0.84–1.10) 35.2 0.187
 Europe 4 0.90(0.81–1.00) 0.0 0.698 2 1.07(1.01–1.09) 0.0 0.522 2 1.05(0.62–1.77) 77.2 0.036 1 0.98(0.66–1.45) NA NA
 Asia 2 4.55 (0.23–89.94) 94.3 0.000
 Australia 2 1.36 (0.98–1.90) 32.9 0.222 1 2.49(1.04–5.93) NA NA
NOS score
 High 10 1.02(0.93–1.13) 61.4 0.006 4 1.02(0.94–1.11) 33.2 0.213 3 1.25(0.79–2.10) 73.2 0.024 5 0.93(0.86–1.00) 0.0 0.612
 Low 3 1.90 (0.29–12.61) 90.6 0.000 2 1.15(0.78–1.70) 0.0 0.715 1 1.25(0.93–1.69) NA NA
Adjusted for confounders or important risk factors Age
 yes 10 1.02(0.88–1.18) 55.6 0.016 5 1.07(1.01–1.13) 0.0 0.951 2 1.59(0.93–2.71) 41.0 0.193 5 0.99(0.82–1.19) 34.1 0.194
 no 3 1.04(0.92–1.17) 73.2 0.000 1 0.95(0.86–1.05) NA NA 1 0.79(0.53–1.18) NA NA 1 0.94(0.86–1.02) NA NA
Race
 yes 2 0.90(0.81–1.00) 0.0 0.769 4 1.07(0.84–1.36) 0.0 0.872 2 0.94(0.87–1.03) 0.0 0.380
 no 11 1.10(0.93–1.29) 69.5 0.000 2 1.02(0.90–1.14) 75.9 0.042 3 1.25(0.74–2.10) 73.2 0.024 4 0.97(0.79–1.18) 44.4 0.145
Cigarette smoking
 yes 8 0.99(0.84–1.17) 62.7 0.009 5 1.03(0.96–1.00) 17.5 0.303 3 1.25(0.74–2.10) 73.2 0.024 3 1.06(0.84–1.33) 48.9 0.142
 no 5 1.17(0.88–1.56) 79.2 0.001 1 1.09(0.74–1.61) NA NA 3 0.88(0.75–1.04) 0.0 0.497
Alcohol drinking
 yes 9 1.07(0.89–1.28) 77.2 0.000 4 1.07(1.01–1.13) 0.0 0.963 2 1.05(0.62–1.77) 77.2 0.036 5 0.99(0.82–1.19) 34.1 0.194
 no 4 1.04(0.83–1.24) 65.8 0.032 2 0.95(0.85–1.05) 0.0 0.843 1 2.49(1.04–5.93) NA NA 1 0.96(0.86–1.06) NA NA
BMI
 yes 7 1.02(0.87–1.20) 62.8 0.013 3 1.01(0.92–1.12) 0.0 0.916 3 1.25(0.79–2.10) 73.2 0.024 2 0.94(0.87–1.02) 0.0 0.839
 no 6 1.08(0.80–1.45) 78.2 0.000 3 1.12(0.85–1.48) 54.9 0.109 4 1.00(0.79–1.26) 50.5 0.108
Table 4.  Results of subgroup analysis of asthma, hay fever, atopy, and any allergy.
Figure 3. Funnel plot of asthma and relative risk of prostate cancer. 
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cancer has been evaluated in a small number of studies. The small number of prior studies evaluating allergic 
disease and prostate cancer has not produced consistent results, inverse12,16,18, null13–15,17,28–31, and positive associ-
ations10,11,19,21–27 have been reported. The inconsistent results of previous studies may be due to insufficient study 
sample size, publication bias, selection bias, lack of adjustment for confounding factors, and the use of different 
definitions of allergic diseases. A recent meta-analysis of the few studies suggested that asthma (N = 8, pooled RR: 
0.93; 95%CI: 0.76–1.15), hay fever (N = 5, pooled RR: 0.96; 95%CI: 0.87–1.05), and any allergy (N = 4, pooled RR: 
1.01; 95%CI: 0.87–1.17), but not for atopy (N = 3, pooled RR: 1.43; 95%CI: 1.08–1.91)20. However, studies pub-
lished subsequent to this report have reported inconsistent results23–31. In addition, the relation between allergic 
diseases and cancer risk remain unclear, and appear to be site-specific, we conducted an up-dated meta-analysis 
to summarize the current proof to evaluate the association between allergic conditions and prostate cancer risk. 
The meta-analysis suggested that there is little observational support for the two theories in the development of 
prostate cancer. The effect of hyperreactive state and/or immune surveillance theories maybe mutually offset in 
the body.
Figure 4. Forest plot of hay fever and relative risk of prostate cancer. 
Figure 5. Forest plot of atopy and relative risk of prostate cancer. 
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The present meta-analysis exhibited several strengths, compared to the previous published meta-analysis. The 
first research highlight of this meta-analysis is its large sample size. The large number of total cases provided high 
statistical power to quantitatively evaluate the association between allergic conditions and prostate cancer risk. In 
addition, we expand the meta-analysis and the association between different geographic regions and study design, 
adjusted for covariates was also explored. Second, publication bias is a potential concern in any meta-analysis 
because small studies with null results do not get published. However, in our meta-analysis, we found little evi-
dence of publication bias.
Nevertheless, there are some several limitations in the present meta-analysis. First, case-control studies have 
intrinsic limitations, such as selective bias and recall or memory bias. This limitation can partly explained the 
different results between case-control and cohort studies in the stratified analysis. Second, we cannot exclude the 
possibility that the observed null relationship between allergic disorders and prostate cancer risk is attributed to 
confounding factors. Majority of the studies were adjusted for potential confounding factors, but not all potential 
confounders were adjusted in every study. Although the allergic conditions and prostate cancer share common 
some potential confounders, such as cigarette smoking, alcohol drinking, old age, BMI and race, in analysis 
stratified by adjusting the smoking status, age, alcohol drinking BMI and race, similar results were obtained. 
Third, measurement error in assessment of allergic conditions are known to bias effect estimates, however, none 
of included studies in the meta-analysis made any corrections for measurement errors. An accurate assessment 
of allergic conditions remains a challenge, because these measures are based on different assessment methods, 
such as allergen-specific IgE measurement, skin prick testing, self-reported questionnaire, interviewed by medical 
staff, and hospital discharge register. Diagnosis of allergic conditions was largely based on a self-reported. Only a 
few studied were based on measurements that may be condisered to be more objective: serum LgE or skin prick 
tests. The increasing errors in measurements become inevitable. The imprecise measurement of allergic disorders 
might have attenuated the true associations. Fourth, potential sources of between-study heterogeneity, which is 
common in meta-analysis, should be explored although the low heterogeneity was found between hay fever or 
atopy and prostate cancer risk. Results from subgroup and sensitivity analysis indicated that geographic region, 
study design, quality of NOS may be potential sources of heterogeneity. Thirds, in subgroup analysis, there was 
a marginally positive association between hay fever and prostate cancer risk in studies that adjusted for age and 
alcohol drinking and conducted in the Europe, but a null association among studies adjusted for cigarette smok-
ing and race. Due to the numerous comparisons and few included studies, this positive finding may have been 
a chance finding. It indicated that more relevant articles are needed to further explore this association. Fifth, 
analysis of the length of the induction period allows for characterising an exposure–outcome relationship and for 
falsifying the pathway assumed. The longer the supposed time sequence between the exposure and the occurrence 
of the outcome, the more crucial to analyze the empirical induction period. The average follow-up ranged from 
5.05 years to 43 years among included cohort studies. Patients were followed up over five years in majority of the 
studies (92.8%). Therefore, the observation period in the included cohort studies covered a reasonable induction 
period. Overall, these limitations may affect our final conclusions.
In the meta-analysis, we found no indication of an association between allergic conditions (asthma, atopy, 
hay fever, or any allergy) and risk of prostate cancer, and there is little observational support for the immune sur-
veillace theory or antigenic stimulation theory in the development of prostate cancer risk. However, these results 
should be carefully interpreted because of the significant heterogeneity among studies and potential confounders. 
Figure 6. Forest plot of any allergy and relative risk of prostate cancer. 
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Additional large-scale and high-quality prospective studies are needed to confirm the association between allergic 
conditions and risk of prostate cancer.
Methods
Literature search. A literature search was performed in March 15, 2016 without restriction to regions, pub-
lication types, or languages. The primary sources were the electronic databases of Pubmed and Embase data-
bases. To identify eligible studies, the main search employed various combinations of Medical Subject Headings 
(MeSH) and non-MeSH terms “prostate carcinoma” OR “prostatic cancer” OR “prostate cancer” OR “prostatic 
carcinoma” combined with “asthma” OR “asthma*” OR “allergy” OR “allerg*” OR “atopy”. The main search was 
completed independently by two investigators. Any discrepancy was solved by consultation of an investigator, not 
involved in the initial procedure. Moreover, the reference lists of all the studies and published systematic reviews, 
meta-analysis were also screened to identify other potentially eligible studies.
Study selection. To minimize the differences between studies, we imposed the following methodological 
restrictions for the inclusion criteria: 1) study design of interest was either cohort or case control study 2) the 
exposure of interest was allergic conditions (asthma, atopy, hay fever and “any allergy”); 3) the outcome was 
prostate cancer; 4) the study reported enough information to extract effect estimates and the corresponding 95% 
confidence intervals. In case of multiple publications, only the most recent or comprehensive one was considered 
eligible. Two authors (JKS and XHY) independently evaluated the eligibility of all retrieved studies and disagree-
ments were resolved through discussion or consultation with a third author (LHG).
Data extraction. Data from the included studies were extracted and summarized independently by two of 
the authors using a pre-standardized data extraction form. Any disagreement was resolved by the senior author 
(ZWD). The following data were extracted from each study: first author, publication year, study design, country, 
sex, total number of cases and subjects for cohort studies, total number of cases and controls for case-control 
studies, assessment methods for allergic diseases, quantitative effect estimates (expressed as an odds ratio, haz-
ard risk, relative risk, standardized mortality ratio, or standardized incidence ration) and 95%CI and variables 
adjusted for in the meta-analysis. The OR in one study18 was not extracted, thus, we computed the crude risk esti-
mates and corresponding CI. Two review authors (SJK and ZJG) independently extracted data from the selected 
studies. Any disagreements were resolved through discussion and consensus.
Quality assessment. Two review authors (SJK and ZJG) independently assessed the risk of bias using the 
Newcastle-Ottawa Scale (NOS), which consists of three factors: patient selection, comparability of the study 
groups, and assessment of outcome. A score of 0–9 (allocated as stars) was allocated to each study50,51. The studies 
achieving six or more stars were considered to be of high quality.
Statistical analysis. Because the incidence of prostate cancer risk was low, the OR/HR was considered as 
approximation of RR, SMR was also considered as equivalent of SIR52. We computed the combined RR and SIR 
and corresponding 95%CI from the estimated reported in each study. The aggregated results and 95%CIs for 
effect sizes were calculated using inverse-variance weighted random-effects meta-analysis, which incorporated 
both within-study and between-study variability53. I2 was used to assess heterogeneity across studies, with I2 val-
ues of 0%, 25%, 50% and 75% representing no, low, moderate and high heterogeneity, respectively. Subgroup anal-
ysis was stratified by geographic region, study design, quality of NOS scale, body mass index (BMI) and whether 
the study adjusted for risk factors, including age, race, alcohol drinking and smoking. The sensitivity analysis was 
also conducted by removing one study at a time and the rest analyzed to determine whether an individual study 
affected the aggregate result or not. Small study bias, consistent with publication bias, was evaluated by statistical 
tests (Begg rank correlation test54 and Egger’s linear regression test55), the visual examination of funnel plot when 
the number of included studies ≥ 10, and the results were considered to indicate publication bias when P < 0.10. 
All statistical analyses were conducted using Stata version 13.1 (Stata Corp., College Station, TX, USA).
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